EDIT vs QURE

Editas Medicine, despite its foundational CRISPR IP and focus on high-TAM genetic diseases with EDIT-301, faces critical challenges. Intense competition, particularly from players with approved therapies, has tightened the window for differentiation. Financial health has deteriorated, with a shortened cash runway and a high probability of further dilutive financing looming. While EDIT-301 shows pr...

uniQure maintains its strong 10x potential within 3-5 years, primarily driven by the transformative promise of AMT-130 for Huntington's disease, addressing a vast unmet medical need with its proprietary AAV5 platform. The foundational success of Hemgenix, generating royalties and milestones via CSL Behring, provides a crucial financial backbone and validates the company's gene therapy capabilities...